Fiche publication
Date publication
janvier 2016
Journal
Transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe
Tous les auteurs :
Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ
Lien Pubmed
Résumé
We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).
Mots clés
Adult, Age Factors, Aged, Australia, Canada, Carcinoma, Hepatocellular, mortality, Disease Progression, Disease-Free Survival, Drug Therapy, Combination, Europe, Female, Humans, Immunosuppressive Agents, therapeutic use, Intention to Treat Analysis, Kaplan-Meier Estimate, Liver Neoplasms, mortality, Liver Transplantation, adverse effects, Male, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Risk Assessment, Risk Factors, Sirolimus, therapeutic use, TOR Serine-Threonine Kinases, antagonists & inhibitors, Time Factors, Treatment Outcome, Young Adult
Référence
Transplantation. 2016 Jan;100(1):116-25
